Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 7;74(1):24-31.
doi: 10.1093/cid/ciab305.

Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study

Rebecca N Kumar  1 , En-Ling Wu  1 , Valentina Stosor  1   2 , William J Moore  3 , Chad Achenbach  1   4 , Michael G Ison  1   2 , Michael P Angarone  1
Affiliations

Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study

Rebecca N Kumar et al. Clin Infect Dis. .

Abstract

Background: Coronavirus disease 2019 (COVID-19) has strained healthcare systems with patient hospitalizations and deaths. Anti-spike monoclonal antibodies, including bamlanivimab, have demonstrated reduction in hospitalization rates in clinical trials, yet real-world evidence is lacking.

Methods: We conducted a retrospective case-control study across a single healthcare system of nonhospitalized patients, age 18 years or older, with documented positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing, risk factors for severe COVID-19, and referrals for bamlanivimab via emergency use authorization. Cases were defined as patients who received bamlanivimab; contemporary controls had a referral order placed but did not receive bamlanivimab. The primary outcome was 30-day hospitalization rate from initial positive SARS-CoV-2 polymerase chain reaction (PCR). Descriptive statistics, including χ 2 and Mann-Whitney U test, were performed. Multivariable logistic regression was used for adjusted analysis to evaluate independent associations with 30-day hospitalization.

Results: Between 30 November 2020 and 19 January 2021, 218 patients received bamlanivimab (cases), and 185 were referred but did not receive drug (controls). Thirty-day hospitalization rate was significantly lower among patients who received bamlanivimab (7.3% vs 20.0%, risk ratio [RR] 0.37, 95% confidence interval [CI]: .21-.64, P < .001), and the number needed to treat was 8. On logistic regression, odds of hospitalization were increased in patients not receiving bamlanivimab and with a higher number of pre-specified comorbidities (odds ratio [OR] 4.19 ,95% CI: 1.31-2.16, P < .001; OR 1.68, 95% CI: 2.12-8.30, P < .001, respectively).

Conclusions: Ambulatory patients with COVID-19 who received bamlanivimab had a lower 30-day hospitalization than control patients in real-world experience. We identified receipt of bamlanivimab and fewer comorbidities as protective factors against hospitalization.Bamlanivimab's role in preventing hospitalization associated with coronavirus disease 2019 (COVID-19) remains unclear. In a real-world, retrospective study of 403 high-risk, ambulatory patients with COVID-19, receipt of bamlanivimab compared to no monoclonal antibody therapy was associated with lower 30-day hospitalization.

Keywords: COVID-19; SARS-CoV-2; bamlanivimab; monoclonal antibody.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study flowchart for inclusion. Abbreviation: mAb, monoclonal antibody.
Figure 2.
Figure 2.
Kaplan-Meier of time to hospitalization after SARS-CoV-2 test. Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
See this image and copyright information in PMC

Comment in

References

    1. WHO coronavirus disease (COVID-19) dashboard. Available at: https://covid19.who.int/. Accessed 28 February.
    1. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins (JHU). Available at: https://coronavirus.jhu.edu/map.html. Accessed 28 February.
    1. FDA. approves first treatment for COVID-19.https://www.fda.gov/news-events/press-announcements/fda-approves-first-t.... Published October 22, 2020. Accessed 20 May 2021.
    1. Ko JY, Danielson ML, Town M, et al. . Risk factors for COVID-19-associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system. Clin Infect Dis 2020. - PMC - PubMed
    1. Williamson EJ, Walker AJ, Bhaskaran K, et al. . Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584:430–6. - PMC - PubMed

Publication types

Substances